Recently, Jinxiang Medical announced the completion of a Series A financing round exceeding 100 million yuan. The funds raised in this round will be used for the research and development, commercial promotion, and regulatory filing of cancer genetic testing products, with the aim of establishing a comprehensive medical service system covering the entire chain of tumor biomarker screening, diagnosis, and treatment based on genetic big data.

As early as 2018, GuChuan United facilitated Jinxiang Medicine’s establishment in the Wuqing Development Zone. With a total investment of 200 million yuan and the leasing of over 3,000 square meters of office space, this laid a solid foundation for the company’s expansion in Wuqing, its foothold in Tianjin, and its long-term development.

In just two years since its establishment in Wuqing, Jinxiang Medicine has grown into one of the few domestic enterprises to achieve leading status in both solid tumors and hematological malignancies. It possesses China’s only proprietary genetic database for urological tumors and the country’s largest genetic database for hematological malignancies. As a benchmark enterprise in the medical sector within the Wuqing Development Zone, it is accelerating the zone’s development into a hub for the medical industry.

Currently, the healthcare industry offers vast development prospects and is a sector receiving strong support from numerous government-led industrial parks across the country. Guchuan United possesses extensive experience in attracting healthcare projects, having successfully facilitated the establishment of leading industry players such as MicroPort Medical, Lepu Medical, and Kangde Pharmaceutical. Moving forward, Guchuan United will continue to leverage its portfolio of 260,000 project resources and its local investment promotion teams across 12 cities to provide more targeted investment promotion services to partners nationwide.